Are Intranasal Sprays The Next $36 Billion Trend in Vaccine Stocks?
It's no secret that coronavirus vaccines are hot-selling medicines for which there's a massive market. Pfizer is expected to make $36 billion in 2021 alone from sales of its coronavirus shot, Comirnaty, and it's hard to see demand falling while the pandemic rages.
Nonetheless, the shots that are currently approved for sale aren't perfect. If a competitor were to develop a new product that doesn't fall victim to the same pitfalls, Pfizer's dominance might come to an end. In my view, intranasal vaccines might well precipitate that outcome. Here's why.
Image source: Getty Images.
Source Fool.com
